Abstract
Background To date, there are no comprehensive data on antibiotic use in children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C).
Methods Multicenter cohort study from 5 Latin American countries. Children 17 years of age or younger with microbiologically confirmed SARS-CoV-2 infection or fulfilling MIS-C definition were included. Antibiotic prescriptions were collected and factors associated with their use were calculated.
Findings 990 children were included, with a median age of 3 years (interquartile range 1–9). Of these, 69 (7.0%) were diagnosed with MIS-C. The prevalence of antibiotic use was 24.5% (n = 243). MIS-C with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X-rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently associated with increased use of antibiotics. On the contrary, lower respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics. There was significant variation in antibiotic use across the hospitals.
Conclusions Our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in children with COVID-19. Prospective studies are needed to provide better evidence on the recognition and management of bacterial infections in COVID-19 children.
What is known COVID-19 may worsen antibiotic prescription practices
What this new COVID-19 and MIS-C children frequently received antibiotics
There was a wide variation in antibiotic prescriptions among institutions, highlighting the lack of practicle guidelines in the use of antibiotics in children with COVID-19
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
nothing to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses: Adriana Yock-Corrales, adriyock{at}gmail.com
Jacopo Lenzi, jacopo.lenzi2{at}unibo.it
Rolando Ulloa-Gutiérrez, rolandoug{at}gmail.com
Jessica Gómez-Vargas, jemagova{at}gmail.com
Antúnez-Montes Omar Yassef, antunezyassef{at}gmail.com
Jorge Alberto Rios Aida, jriosaida{at}gmail.com
Olguita del Aguila, odaguila{at}hotmail.com
Erick Arteaga-Menchaca, docarteaga{at}hotmail.com
Francisco Campos, francisco.e.campos{at}gmail.com
Fadia Uribe, kafaur87{at}hotmail.com
Andrea Parra Buitrago, aparra{at}neumologica.org
Lina Maria Betancur Londoño, lina_b16{at}yahoo.com
Martin Brizuela, martin.brizuela1984{at}gmail.com
Danilo Buonsenso, danilobuonsenso{at}gmail.com
Data Availability
available upon request
List of Abbreviation
- COVID-19
- coronavirus disease 2019
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- MIS-C
- multisystem inflammatory syndrome in children
